drugset
drugset / Trial / NCT05128591

A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091

NCT05128591 ↗

Phase 1 Completed 38 enrolled Addpharma Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-109 in healthy male subjects.

Timeline

Start
2021-11-09
Primary completion
2021-12-31
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivaroxaban Other / unclassified 18 mg Oral
Subject Rivaroxaban Other / unclassified 20 mg Oral

Indications

thrombotic disease